(ICLR) ICON - NASDAQ
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 11.479m USD | Total Return: 3% in 12m
Avg Turnover: 159M
EPS Trend: -18.3%
Qual. Beats: -2
Rev. Trend: 42.8%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
No distinct edge detected
ICON Public Limited Company (ICLR) is a Dublin-based Clinical Research Organization (CRO) providing comprehensive outsourced development and commercialization services. The company operates across the full clinical trial lifecycle, managing programs from compound selection through Phase I-IV studies. Its service portfolio includes laboratory testing, site and patient access, data solutions, and post-market commercialization for pharmaceutical, biotechnology, and medical device clients.
The CRO business model relies on the increasing trend of pharmaceutical companies outsourcing R&D to manage costs and access specialized expertise. As a major player in the Life Sciences Tools & Services sector, ICON utilizes functional service partnerships (FSPs) to provide clients with dedicated staff and infrastructure, reducing the fixed-cost burden on drug developers. The industry is currently shifting toward decentralized clinical trials (DCTs) to increase patient recruitment and retention rates.
Investors may find further insights on the companys valuation metrics by reviewing the data on ValueRay. Founded in 1989, ICON maintains a global footprint with a strategic focus on integrated clinical trial networks and real-world intelligence to streamline the drug approval process.
- Biotechnology funding levels dictate demand for early-stage clinical trial services
- Strategic functional service provider partnerships stabilize long-term recurring revenue streams
- Labor cost inflation and personnel retention impact core operating margins
- Integration of decentralized trial technologies improves patient enrollment and retention
- Global pharmaceutical R&D budget shifts determine Phase II-IV study volume
| Net Income: 483.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.27 > 1.0 |
| NWC/Revenue: 3.69% < 20% (prev 8.87%; Δ -5.18% < -1%) |
| CFO/TA 0.13 > 3% & CFO 2.11b > Net Income 483.7m |
| Net Debt (3.06b) to EBITDA (1.27b): 2.41 < 3 |
| Current Ratio: 1.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (79.0m) vs 12m ago -3.98% < -2% |
| Gross Margin: 23.89% > 18% (prev 29.00%; Δ -5.12% > 0.5%) |
| Asset Turnover: 50.22% > 50% (prev 48.99%; Δ 1.23% > 0%) |
| Interest Coverage Ratio: 4.93 > 6 (EBIT TTM 889.6m / Interest Expense TTM 180.6m) |
| A: 0.02 (Total Current Assets 3.50b - Total Current Liabilities 3.20b) / Total Assets 16.3b |
| B: 0.13 (Retained Earnings 2.12b / Total Assets 16.3b) |
| C: 0.05 (EBIT TTM 889.6m / Avg Total Assets 16.5b) |
| D: 1.30 (Book Value of Equity 9.19b / Total Liabilities 7.08b) |
| Altman-Z'' = 2.27 = BBB |
| DSRI: 0.99 (Receivables 2.75b/2.74b, Revenue 8.29b/8.19b) |
| GMI: 1.21 (GM 29.00% / 23.89%) |
| AQI: 0.98 (AQ_t 0.75 / AQ_t-1 0.76) |
| SGI: 1.01 (Revenue 8.29b / 8.19b) |
| TATA: -0.10 (NI 483.7m - CFO 2.11b) / TA 16.3b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of June 12, 2026, the stock is trading at USD 149.92 with a total of 790,289 shares traded.
Over the past week, the price has changed by -1.88%,
over one month by +26.03%,
over three months by +42.27% and
over the past year by +3.01%.
ICON has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ICLR.
- StrongBuy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 153.3 | 2.2% |
P/E Trailing = 51.5189
P/E Forward = 14.3062
P/S = 1.3912
P/B = 1.2475
P/EG = 0.4948
Revenue TTM = 8.29b USD
EBIT TTM = 889.6m USD
EBITDA TTM = 1.27b USD
Long Term Debt = 2.87b USD (from longTermDebt, last fiscal year)
Short Term Debt = 566.0m USD (from shortTermDebt, last quarter)
Debt = 3.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 153.4m
Net Debt = 3.06b USD (calculated: Debt 3.71b - CCE 647.3m)
Enterprise Value = 14.5b USD (11.5b + Debt 3.71b - CCE 647.3m)
Interest Coverage Ratio = 4.93 (Ebit TTM 889.6m / Interest Expense TTM 180.6m)
EV/FCF = 8.43x (Enterprise Value 14.5b / FCF TTM 1.72b)
FCF Yield = 11.86% (FCF TTM 1.72b / Enterprise Value 14.5b)
FCF Margin = 20.82% (FCF TTM 1.72b / Revenue TTM 8.29b)
Net Margin = 5.84% (Net Income TTM 483.7m / Revenue TTM 8.29b)
Gross Margin = 23.89% ((Revenue TTM 8.29b - Cost of Revenue TTM 6.31b) / Revenue TTM)
Gross Margin QoQ = 22.76% (prev 22.76%)
Tobins Q-Ratio = 0.89 (Enterprise Value 14.5b / Total Assets 16.3b)
Interest Expense / Debt = 4.87% (Interest Expense 180.6m / Debt 3.71b)
Taxrate = 6.67% (10.7m / 159.9m)
NOPAT = 830.3m (EBIT 889.6m * (1 - 6.67%))
Current Ratio = 1.10 (Total Current Assets 3.50b / Total Current Liabilities 3.20b)
Debt / Equity = 0.40 (Debt 3.71b / totalStockholderEquity, last quarter 9.19b)
Debt / EBITDA = 2.41 (Net Debt 3.06b / EBITDA 1.27b)
Debt / FCF = 1.78 (Net Debt 3.06b / FCF TTM 1.72b)
Total Stockholder Equity = 9.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.93% (Net Income 483.7m / Total Assets 16.3b)
RoE = 5.19% (Net Income TTM 483.7m / Total Stockholder Equity 9.32b)
RoCE = 7.30% (EBIT 889.6m / Capital Employed (Equity 9.32b + L.T.Debt 2.87b))
RoIC = 6.28% (NOPAT 830.3m / Invested Capital 13.2b)
WACC = 8.30% (E(11.5b)/V(15.2b) * Re(9.51%) + D(3.71b)/V(15.2b) * Rd(4.87%) * (1-Tc(0.07)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.93 | Cagr: -2.25%
[DCF] Terminal Value 77.97% ; FCFF base≈1.46b ; Y1≈1.67b ; Y5≈2.46b
[DCF] Fair Price = 443.5 (EV 37.0b - Net Debt 3.06b = Equity 34.0b / Shares 76.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -18.29 | EPS CAGR: -1.46% | SUE: -3.55 | # QB: -2
Revenue Correlation: 42.80 | Revenue CAGR: 0.76% | SUE: 1.17 | # QB: 4
EPS current Quarter (2026-06-30): EPS=2.55 | Chg30d=-12.46% | Revisions=-45% | Analysts=13
EPS current Year (2026-12-31): EPS=10.54 | Chg30d=-10.87% | Revisions=-47% | GrowthEPS=-15.9% | GrowthRev=-2.8%
EPS next Year (2027-12-31): EPS=11.70 | Chg30d=-8.48% | Revisions=-47% | GrowthEPS=+11.0% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -47%